Distinguishing inflammatory Th17 subsets through using an autoimmune Th17-selective inhibitor
通过使用自身免疫 Th17 选择性抑制剂区分炎症 Th17 亚群
基本信息
- 批准号:10814571
- 负责人:
- 金额:$ 20.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-12 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAffectAmericanAntibody TherapyAutoimmuneAutoimmune DiseasesAutoimmunityBacterial InfectionsBiological AssayCD4 Positive T LymphocytesCell SeparationCellsCentral Nervous SystemClinical TreatmentDataDevelopmentDiseaseExperimental Autoimmune EncephalomyelitisExposure toGene ExpressionGene Expression ProfileGenerationsGenesGeneticGoalsHumanIL17 geneIn VitroInfectionInfection ControlInflammatoryInterferon Type IIInterleukin-6IntestinesKnock-outKnowledgeLeukocytesMetabolicMissionModelingMonoclonal AntibodiesMusMycosesOutcomePathogenicityPatientsPhysiologicalPlayPoint MutationPredispositionPublic HealthRegulationRepressionResearchResearch Project GrantsResistanceRiskRoleSerineTestingTherapeuticTransforming Growth Factor betaTuberculosisUnited States National Institutes of Healthcytokinedisabilityevidence baseexperimental studyextracellularfightinggene regulatory networkin vivoinhibitorinnovationinterleukin-23mRNA Differential Displaysmicrobiotamouse modelnovelnovel therapeuticspathogenpharmacologicprogramsresponseside effectsingle-cell RNA sequencingsmall moleculesynthetic enzyme
项目摘要
Project Summary
Th17 cells are a subset of IL-17-producing T helper CD4+ T cells and play a pivotal role in the pathogenicity of a
variety of autoimmune diseases, which are affecting over 23 million Americans with no cure. Knowledge about
regulatory mechanisms of Th17 cells might offer new opportunities for treating these diseases. Based on the
requirement of IL-23 for the development, Th17 cells are currently divided into IL-23-independent homeostatic
and IL-23-dependent inflammatory Th17 cells, of which the latter execute both physiological (clearing
extracellular pathogen infections) and pathogenic (eliciting autoimmunity) functions. Substantial efforts have
been made to define gene regulatory networks that discriminate homeostatic and inflammatory Th17 cells.
However, how to dissect the subsets of inflammatory Th17 cells is largely unknown. This knowledge is
critically needed because non-selective suppression of inflammatory Th17 cells, as by the newly approved IL-
23 monoclonal antibody-based therapy for autoimmune diseases, inevitably increases susceptibility to fungal
and bacterial infections. Herein, autoimmune and anti-infection Th17 subsets display differential responses to
the small molecule Clofazimine: the autoimmune effect of Th17 subsets was repressed while the anti-infection
function of Th17 subsets was not disturbed. Our overall objectives in this application are to elucidate the gene
expression and metabolic programs discriminating autoimmune and anti-infection Th17 subsets. The central
hypothesis is that autoimmune and anti-infection Th17 subsets are distinguishable and SHMT1 is a checkpoint
of intracellular serine levels in autoimmune Th17 cells. The rationale for this project is that determination of the
differences between autoimmune and anti-infection Th17 subsets is likely to offer a strong scientific framework
whereby new strategies to autoimmune diseases therapy with substantially increased selectivity and reduced
adverse effects can be developed. The central hypothesis will be tested by pursuing two specific aims: Aim 1)
To identify gene expression signatures of anti-infection and autoimmune Th17 subsets in vivo; and Aim 2) To
determine the role of SHMT1 in regulating intracellular serine in autoimmune Th17 cells. Under Aim 1, single-
cell RNA-seq analysis will be utilized with verification using Cas9-based knockout assay. For Aim 2, the
pathogenicity of autoimmune Th17 cells and their intracellular serine levels will be evaluated in the presence of
SHMT1 modulation: pharmacologic inhibition, genetic knockout, and point mutation with inactive enzymatic
activities. The research proposed in this application is innovative, because it focuses on the regulatory network
discriminating anti-infection and autoimmune Th17 subsets, a heretofore-unexamined mechanism. The
proposed research is significant because it is expected to provide novel opportunities to develop autoimmune
Th17-selective therapeutics for autoimmune diseases. This would be extraordinarily important for patients that
have been infected or exposed to certain pathogens, such as tuberculosis, since existing Th17 inhibitors cannot
be used due to the risks of decreasing the patients’ control of the infection.
项目摘要
Th17细胞是产生IL-17的辅助性T细胞CD4+T细胞的一个亚群,在非霍奇金淋巴瘤的致病过程中起关键作用。
各种自身免疫性疾病,这些疾病正在影响着2300多万无法治愈的美国人。了解以下内容
Th17细胞的调控机制可能为治疗这些疾病提供新的机会。基于
需要IL-23的发育,目前Th17细胞处于非IL-23的稳态状态
和IL-23依赖的炎性Th17细胞,后者执行生理(清除
细胞外病原体感染)和致病(引发自身免疫)功能。已经做出了重大努力
被用来定义区分稳态和炎症性Th17细胞的基因调控网络。
然而,如何解剖炎性Th17细胞亚群在很大程度上是未知的。这一知识是
非常需要,因为对炎性Th17细胞的非选择性抑制,就像新批准的IL-
23基于单抗的自身免疫性疾病治疗不可避免地增加了对真菌的易感性
和细菌感染。在此,自身免疫和抗感染的Th17亚群对
小分子氯法齐明:在抗感染的同时抑制Th17亚群的自身免疫效应
Th17亚群功能未受影响。我们在这项应用中的总体目标是阐明基因
表达和代谢程序区分自身免疫和抗感染Th17亚群。中环
假设自身免疫和抗感染的Th17亚群是可区分的,SHMT1是一个检查点
自身免疫Th17细胞内丝氨酸水平的变化。这个项目的基本原理是确定
自身免疫和抗感染Th17亚群之间的差异可能提供一个强有力的科学框架
因此,自身免疫性疾病治疗的新策略大大增加了选择性,减少了
可能会产生不良影响。核心假设将通过追求两个具体目标来检验:目标1)
鉴定体内抗感染和自身免疫Th17亚群的基因表达特征;并目的2)
确定SHMT1在自身免疫性Th17细胞内丝氨酸调节中的作用。在目标1下,单一-
细胞RNA-seq分析将利用基于Cas9的基因敲除分析进行验证。对于目标2,
自身免疫Th17细胞的致病性及其细胞内丝氨酸水平将在存在
SHMT1的调节:药物抑制、基因敲除和失活酶的点突变
活动。本申请中提出的研究具有创新性,因为它关注的是监管网络
区分抗感染和自身免疫的Th17亚群,这是一种迄今未被研究的机制。这个
提出的研究具有重要意义,因为它有望为发展自身免疫提供新的机会
TH17-自身免疫性疾病的选择性治疗。这对患者来说非常重要,
已感染或接触某些病原体,如结核病,因为现有的Th17抑制剂不能
由于降低患者对感染的控制的风险而使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhiheng He其他文献
Zhiheng He的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhiheng He', 18)}}的其他基金
Distinguishing inflammatory Th17 subsets through using an autoimmune Th17-selective inhibitor
通过使用自身免疫 Th17 选择性抑制剂区分炎症 Th17 亚群
- 批准号:
10527102 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Determining the mechanisms by which a circular RNA regulates the function of Th17 cells
确定环状 RNA 调节 Th17 细胞功能的机制
- 批准号:
10509244 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Determining the mechanisms by which a circular RNA regulates the function of Th17 cells
确定环状 RNA 调节 Th17 细胞功能的机制
- 批准号:
10814585 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Dissecting functions of IL-23-dependent inflammatory Th17 cells
解析 IL-23 依赖性炎症 Th17 细胞的功能
- 批准号:
10815237 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Dissecting functions of IL-23-dependent inflammatory Th17 cells
解析 IL-23 依赖性炎症 Th17 细胞的功能
- 批准号:
10566390 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 20.68万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 20.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 20.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 20.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 20.68万 - 项目类别:
Discovery Grants Program - Individual